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ABSTRACT
Toll-like receptors (TLRs) have been widely investigated due to their importance 
in the inflammatory response and possible links to tumor promotion/regression and 
prognosis. In cancers with an infective etiology, such as human papillomavirus (HPV)-
associated Oropharyngeal Squamous Cell Carcinoma (OPSCC), TLR responses may 
be activated and play a role in tumorigenesis. Our aim was to assess the expression 
of all TLRs in OPSCC cell lines (both HPV+ and HPV) by qPCR, Western Blot and flow 
cytometry and assess their response to TLR ligands lipopolysaccharide (LPS), LPS 
ultra-pure (LPS-UP) and peptidoglycan (PGN) by analyzing IL-8 and IL-6 production. 
We also immunostained 61 OPSCC tissue samples with anti-TLR4. Results showed 
lower TLR1 and TLR6 mRNA expression and higher TLR9 protein expression in HPV+ 
when compared to HPVOPSCC cells. TLR4 expression did not vary by HPV status 
in OPSCC cells, but TLR4 expression was significantly lower in HPV+OPSCC tissues. 
After stimulation with PGN, only one cell line (HPV+) did not secrete IL-6 or IL-8. 
Furthermore, HPV+OPSCC lines showed no IL-6 or IL-8 production on treatment with 
LPS/LPS-UP. The data suggest changes in TLR4 signaling in HPV+OPSCC, since we 
have shown lower tissue expression of TLR4 and no pro-inflammatory response after 
stimulation with LPS and LPS-UP. Also, it suggests that OPSCC may respond to HPV 
infection by increased expression of TLR9. This study demonstrates differences in 
expression and function of TLRs in OPSCC, which are dependent on HPV status, and 
may indicate subversion of the innate immune response by HPV infection. 
INTRODUCTION
The innate immune response detects pathogenic 
microorganisms through a number of mechanisms, 
including recognition of pathogen-associated molecular 
patterns (PAMP) by pattern-recognition receptors 
(PRRs), which include the Toll-like receptors (TLR) [1]. 
Most epithelial cells express TLRs, as well as relevant 
co-receptors and adapter molecules, such as MyD88 
and CD14 [2]. The near-ubiquitous nature of TLR 
expression within normal epithelia relates to its important 
barrier function against invading microorganisms; TLR 
activity is essential for an effective host response to be 
mounted [3]. In addition to this central role in protection 
against infection, TLRs have roles in maintaining tissue 
homeostasis through the regulation of inflammatory and 
reparative responses to tissue injury [4].
Over 150 years ago, Virchow demonstrated a 
connection between inflammation and cancer by observing 
leucocytes within tumor tissue. Today, there is a wide 
consensus on the importance of the inflammatory response 
in tumor propagation and as a risk factor for carcinogenesis 
[5]. Inflammation can exert anti-apoptotic effects, induce 
oxidative DNA damage and promote a tissue reparative 
response. Concomitantly, the adaptive immune response is 
also important in tumor progression [6]. The link between 
the immune system and cancer progression has led several 
groups to assess the role of receptors capable of activating 
signaling pathways for the recruitment of inflammatory 
cells, among which are included the TLRs. 
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Although the TLR system has the capacity to 
respond to a range of microbial factors, individual TLRs 
demonstrate relatively high ligand specificity. TLR1, 
TLR2 and TLR6 primarily recognize peptidoglycan 
(PGN), lipoteichoic acid and zymogen; TLR3, double 
stranded RNA; TLR4, lipopolysaccharides (LPS) of 
Gram-negative bacteria; TLR5, bacterial flagellum; TLR7 
and TLR8, single-stranded RNA; TLR9, bacterial and 
viral unmethylated CpG DNA [1, 4]. TLR10 is the only 
receptor without a specific known ligand [7].
Changes in the expression of TLRs or their signaling 
pathways may lead to progression or regression of the 
tumor, depending on cancer type [8]. Many studies have 
focused on the role of TLRs in cancer immunotherapy 
[810]; although results vary depending on cancer type 
and location. Individual studies are therefore necessary in 
order to assess the role of TLRs in a given cancer type, 
as the effects of TLR activation appear to be context-
dependent and therefore cannot be predicted from data 
relating to other tumors. 
Patients with HPV+ OPSCC have a better prognosis 
than those with HPV-negative disease [11, 12], but so 
far there are few studies correlating OPSCC HPV status 
to immune response [13]. In addition, studies in cervical 
cancer have shown changes in the innate immune response 
linked to the expression of TLRs [14, 15]. In oropharyngeal 
cancer, only two studies have been published that have 
evaluated Toll-like receptors expression [13, 16].
Our overall aim was to describe the patterns of 
expression of all TLRs in HPV+ and HPV OPSCC, and 
determine the function of selected receptors after stimulation 
with LPS and PGN, in order to determine the extent of 
alterations in TLR expression and function in OPSCC.
RESULTS
TLR1 and TLR6 
The same pattern of mRNA expression was seen for 
TLR1 (Figure 1A and 1B) and TLR6 (Figure 1C and 1D). 
Under unstimulated conditions, there were significantly 
higher levels of TLR1 and TLR6 gene expression in 
cell lines SCC72 and SCC89 (HPV-) when compared to 
lines SCC2 and SCC90 (HPV+), p < 0.0001. Significant 
differences of TLR1 gene expression were also noted 
between HPV cell lines (SCC72 and SCC89), p < 0.05 
(Figure 1A). Despite differences in mRNA expression, 
there were no significant differences in TLR1 or TLR6 
protein expression when comparing HPV+ and HPV cell 
lines, as measured by flow cytometry (Figure 1B). 
TLR2
There was significantly lower expression of TLR2 
mRNA in SCC72 compared to the other cell lines (SCC89, 
SCC2 and SCC90), p < 0.01 (Figure 2A). Significant 
differences were also noted between SCC90 and all other 
cell lines. Again, despite findings at the mRNA level, there 
were no differences in TLR2 protein expression when 
analyzed by flow cytometry (Figure 2B). 
TLR2 expression after stimulation with PGN
PGN stimulation of cell lines led to no significant 
change in TLR2 mRNA expression, with the exception 
of SCC72, p < 0.001 (Figure 2C), but it was possible 
to demonstrate higher expression of TLR2 protein in 
response to PGN in all cell lines (Figure 2D).
Pro-inflammatory (IL-6 and IL-8) response after 
PGN stimulation
PGN stimulation of the cell line SCC72 (HPV-) did 
not demonstrate significant change in IL-6 expression 
(Figure 3A and 3B). However, PGN treatment led to 
higher expression of IL-8 mRNA after stimulation with 
1 µg/mL PGN (Figure 3C) and higher protein expression 
after 10 µg/mL PGN, p < 0.001 (Figure 3C). 
After 1 µg/mL PGN stimulation, SCC89 (HPV-) 
demonstrated an increase in IL-6 mRNA expression 
(Figure 3A), as well as significantly higher cytokine 
secretion after stimulation with 0.1 µg/mL and 1 µg/mL 
PGN (Figure 3B), p < 0.0001, when compared to 
unstimulated control. In the same way, SCC89 demonstrated 
significantly higher IL-8 protein secretion after stimulation 
with 1 µg/mL and 10 µg/mL PGN (Figure 3D), p < 0.01. 
Despite the changes seen at the protein level, there was 
no significant change in IL-8 mRNA expression under 
stimulated conditions (Figure 3C). 
There was no increase in IL-6 secretion in both HPV+ 
cell lines. Although SCC2 (HPV+) demonstrated higher 
levels of IL-6 mRNA in response to PGN (Figure 3A), 
no change was noted at the protein level (Figure 3B). 
Similarly, SCC90 (HPV+) did not express IL-6 or IL-8 
at either the mRNA or protein level under either basal or 
stimulated conditions, p < 0.001 (Figure 3B and 3D). 
 SCC90 (HPV+) was the only OPSCC cell line tested 
which did not show any pro-inflammatory response to PGN 
stimulation; cell line SCC2 did exhibit increased IL-8 mRNA 
and protein expression after stimulation with 1 µg/mL PGN 
(Figure 3C) and also protein expression after 1 µg/mL 
and 10 µg/mL PGN stimulation, p < 0.01 (Figure 3D). 
TLR4
TLR4 mRNA expression, but not protein expression, 
varies by HPV status in vitro
The relative TLR4 gene expression results showed 
significant differences between SCC90 and the other 
OPSCC cell lines (SCC72, SCC89 and SCC2), p < 0.0001 
(Figure 4A). No significant difference between cell lines 
was seen in the TLR4 protein expression (Figure 4B).
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TLR4 expression after stimulation with LPS and 
LPS-UP
After stimulation with the TLR4 agonist LPS, 
SCC72 showed significantly higher TLR4 expression in 
comparison to SCC2 (p < 0.01), however there was no 
consistent difference between HPV+ and HPV groups 
(Figure 4C). After stimulation with LPS-UP, SCC89 
showed significantly higher mRNA expression of TLR4 
in comparison to the other OPSCC cell lines, p < 0.01 
(Figure 4D). 
Lower expression of TLR4 in HPV+ OPSCC 
tissues
Immunohistochemical staining was restricted to 
cell membrane and/or the cytoplasm. No nuclear staining 
was identified in any of the samples. Significantly lower 
expression of TLR4 was observed in HPV+ tumors when 
compared to HPV tumors, p < 0.0001 (Figure 4E and 4F). 
HPV-associated OPSCC shows no consistent 
pro-inflammatory (IL-6 or IL-8) response after 
stimulation with LPS and LPS-UP 
There was no change in IL-6 (Figure 5A5D) or 
IL-8 gene expression or protein secretion (Figure 5E5H), 
after LPS and LPS-UP stimulation in SCC2 and SCC90. 
However, the HPV cell lines (SCC72 and SCC89) 
increased production of IL-6 or IL-8 (Figure 5). 
Stimulation of SCC72 (HPV) with either LPS or 
LPS-UP, led to both increased IL-8 mRNA expression 
(Figure 5E and 5F) and protein secretion (Figure 5G 
and 5H) over all concentrations tested. Furthermore, 
IL-6 mRNA expression was increased after stimulation 
with 1 µg/mL LPS or LPS-UP (Figure 5A and 5B), in 
Figure 1: Expression of TLR1 and TLR6 in HPV (SCC72 and SCC89), HPV16+ (SCC2 and SCC90) and HPV18+ 
(Hela). (A) TLR1 mRNA expression relative to SCC72, by qPCR: significant higher levels of gene expression in SCC72 and SCC89 cell 
lines (HPV-) when compared to SCC2, SCC90 (HPV+); (B) TLR1 protein expression: Median Fluorescence intensity (MFI), analyzed by 
flow cytometry, did not show significant differences between cell lines (Median ± SD). (C) TLR6 mRNA expression relative to SCC72: 
significant higher levels of gene expression in SCC72 and SCC89 cell lines (HPV-) when compared to SCC2, SCC90 (HPV+); (D) TLR6 
protein expression: did not show significant differences between cell lines (Median ± SD). (* p < 0.05; ****p < 0.0001; Median ± SEM).
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comparison to unstimulated control, however increased 
protein secretion was not detected (Figure 5C and 5D). 
In SCC89 (HPV), after stimulation with 1 µg/mL 
of LPS or LPS-UP, higher gene expression of IL-6 was 
detected compared to unstimulated control (Figure 5A 
and 5B). This result mirrors findings changes in protein 
expression, where elevated concentrations of IL-6 were 
detected by ELISA after stimulation with 0.1 µg/mL and 
1 µg/mL LPS (Figure 5C) or 1 µg/mL LPS-UP (Figure 5D). 
LPS treatment also resulted in higher IL-8 gene expression 
in SCC89 (Figure 5E), however no significant difference 
was observed in IL-8 protein secretion.
TLR9
There were no significant differences in overall 
TLR9 mRNA expression on comparison of HPV+ and 
HPV cell lines, but the expression of TLR9 mRNA 
was higher in SCC72 than SCC2 (Figure 6A), p < 0.05. 
Despite no difference at mRNA expression, higher TLR9 
protein expression was seen in HPV+ cell lines (SCC2 
and SCC90) compared to HPV cell lines (SCC89 and 
SCC90), as measured by flow cytometry (Figure 6B). 
TLR3, 5, 7, 8 and 10 
No evidence of significant differences in TLR 3, 
5, 7, 8 or 10 gene expression between HPV+ and HPV 
lineages were noted. However, TLR3, without stimulation, 
demonstrated a significant difference in relative gene 
expression between SCC89 and the other cell lines 
studied (SCC72, SCC2 and SCC90) (Supplementary 
Figure 2), also a higher gene expression of TLR5 in 
SCC72 compared to SCC89, SCC2 and SCC90, as well as 
between SCC90 and both SCC2 and SCC89 was observed 
(Supplementary Figure 2). TLR7 did not show significant 
Figure 2: Expression of TLR2 in HPV (SCC72 and SCC89), HPV16+ (SCC2 and SCC90) and HPV18+ (Hela). 
(A) TLR2 gene expression relative to SCC72, by qPCR, shows significant difference between SCC72 and the other cell lines and between 
SCC89 and SCC2 compared to SCC90 (Median ± SEM, p < 0.01); (B) Median Fluorescence intensity (MFI), analyzed by flow cytometry: 
no significant difference between cell lines (Median ± SD), (C) TLR2 gene expression relative to SCC72 after PGN stimulus: SCC72 
showed a significant difference between control and stimulated cells (Median ± SEM, p < 0.001); (D) Comparison of TLR2 expression 
between control (not stimulated) and cells stimulated with PGN: after stimulus all the cell lines expressed TLR2 (cropped gel). THP1 was 
used as control.
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differences between HPV+ and HPV and the only cell line 
which expressed the gene was SCC89. There was no gene 
expression of TLR8 and TLR10 of the OPSCC cell lines 
used in this study. 
DISCUSSION
HPV-associated OPSCC shows clinical, pathological 
and biologically distinct features, due to viral activity 
within tumour tissue [17, 18]. HPV integrates into the host 
genome and expresses oncoproteins E6 and E7, which 
inactivate p53 and retinoblastoma (Rb), respectively and 
dysregulates the cell cycle [19]. HPV also appears to 
modify the expression and functionality of TLRs in cervical 
cancer [14, 15, 20, 21]. Mammalian TLRs help clear 
microbial infection [22], and have been correlated with both 
progression and regression of malignant tumors [8]. 
In this study, where we evaluated TLR 1-10 mRNA 
expression by qPCR, we observed that only TLR1 
and TLR6 mRNA are more expressed in HPV when 
compared to HPV+ cell lines. Despite this finding, there 
were no significant differences in membranous TLR1 
and TLR6 expression on comparing HPV+ and HPV 
OPSCC cells. De Carlo reported a similar decrease in 
TLR1 gene expression in HPV+ cervical cancers [23]. In 
an animal model, synthetic bacterial lipoprotein (TLR1 
agonist) induced tumor regression by increasing cytotoxic 
T lymphocyte function [24]. The concept of a universal 
role for TLR1 in tumor regression is however undermined 
by data suggesting that it may promote esophageal 
adenocarcinoma [8].
The lack of any difference in TLR2 expression at 
either gene or protein level, between HPV+ and HPV 
cell lines, led us to assess the functionality of TLR2 after 
stimulation with PGN (a TLR2 agonist). PGN from S. 
aureus is an activator of TLR2 [25] and increases TLR2 
expression after treatment, as observed in our work and 
similarly reported in the literature [25]. HPV lines SCC72 
Figure 3: Comparison of IL-6 and IL-8 expression between non stimulated cells and cells stimulated with peptidoglycan 
(PGN). (A) IL-6 mRNA expression, relative to SCC72, was significantly increased in SCC89 and SCC2 after stimulation with 1 µg/mL 
(*p < 0.05; mean ± SEM); (B) Protein expression of IL-6 was increased in SCC89 after stimulation with 0.1 and 1 µg/mL PGN 
(*p < 0.0001; mean ± SD); (C) IL-8 mRNA expression, relative to SCC72, was significantly increased in SCC89 and SCC2 after stimulation 
with 1 µg/mL of PGN (**p < 0.001; mean ± SEM); (D) Protein expression of IL-8 was increased in SCC72 after stimulation with 10 µg/mL, 
and SCC89 and SCC2 after stimulation with 1 and 10 µg/mL of PGN (*p < 0.01, **p < 0.0001; mean ± SD).
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and SCC89 expressed IL-8 and IL-6, respectively, after 
stimulation with PGN. The HPV+ cell line SCC2 also 
expressed IL-8 after stimulation. This suggests functional 
TLR2 in HPV and HPV+ cells. However, intracellular 
receptors such as NOD (nucleotide-binding oligomerization 
domain) 1 and NOD2 can recognized peptides derived from 
the degradation of PGN. If NOD1 or NOD2 are stimulated, 
it could induce secretion of interleukins [26, 27], thus more 
studies are required to verify the true involvement of. TLR2 
in HPV-associated OPSCC. 
TLR4, a cell membrane receptor, has also been 
implicated in tumor promotion [8]. Immunohistochemical 
analysis of tumor specimens confirmed significantly lower 
expression of TLR4 protein in HPV+ tumors compared 
to HPV tumors ex-vivo. This finding is consistent with 
previous work assessing HPV- associated HNC [16]. Our 
in vitro findings suggested no clear relationship between 
TLR4 gene expression in HPV+ versus HPV cell lines; 
all cell lines expressed TLR4 when assessed by flow 
cytometry. Despite conflicting with ex-vivo findings, our 
in vitro work is also consistent with data published by 
Jouhi et al [13]. 
Unlike the upregulated release of inflammatory 
mediators observed in response to PGN, stimulation with 
LPS and LPS-UP resulted in no change in IL-6 or IL-8 
expression in HPV+ cell lines, although we noted variable 
increased secretion of IL-6 and IL-8 in HPV cell lines. 
The lack of response in HPV+ lines may suggest changes 
in the TLR4 signaling pathway as a consequence of 
viral infection. In cervical cancer, the reported changes 
in expression of TLR4 are a source of controversy and 
effects seen may be related to the HPV type and different 
material and methods used; the cervical carcinoma lines 
SiHa (HPV16+) show higher expression of TLR4 than 
HeLa (HPV18+), moreover SiHa, but not HeLa display 
resistance to apoptosis following treatment with LPS, 
via TLR4 [21]. In cervical carcinoma, some authors have 
demonstrated high TLR4 expression [21, 28], whilst others 
demonstrated low TLR4 expression, linked to histological 
grade [14]. However, not all studies reported the HPV 
subtype involved. Interestingly, lack of or block of TLR4, 
IL-6 and IL-8 in many tumors has been related to better 
treatment response and prognosis [8, 2933], responses 
also seen in HPV-associated OPSCC [11, 12, 34]. 
Many carcinomas have been found to express 
high levels of IL-6 and/or IL-8, suggesting an important 
role of these cytokines in the tumor microenvironment 
[35, 36]. IL-6 is implicated with a number of defense 
mechanisms, in normal tissue, as well as control of 
growth and differentiation in various malignancies [36]. 
Overexpression of IL-6 is also associated with tumor 
progression by inhibition of apoptosis [36], stimulation 
Figure 4: TLR4 expression. (A) TLR4 gene expression, relative to SCC72, showed significant difference between SCC90 and the other 
cell lines; no significant differences between both HPVs- and both HPVs+, by qPCR (target gene normalized to U6) (**p < 0.0001; Mean ± 
SEM); (B) Median Fluorescence intensity (MFI) showed no significant difference between cell lines, by flow cytometry (Mean ± SD); (C) 
TLR4 expression, relative to SCC72, between non stimulated cells and cells stimulated with LPS: significant higher difference between 
SCC72 and SCC2 (*p < 0.01; mean ± SEM); (D) TLR4 expression between non stimulated cells and cells stimulated with LPS ultra pure 
(LPS-UP): significant difference between SCC89 and the other cell lines (*p < 0.01; mean ± SEM); (E) anti-TLR4 stain in HPV tumors and 
HPV+ tumors: Lower expression of TLR4 in HPV-associated OPSCC; (F) Box and whisker plot of TLR4 stain in HPV and HPV+ OPSCC: 
significantly higher stain in HPV tumors (p < 0.0001).
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Figure 5: HPV-associated OPSCC shows no pro-inflammatory IL-6 or IL-8 response after stimulation with LPS and 
LPS ultra pure (LPS-UP). (A) and (B) IL-6 mRNA expression, relative to the untreated, show increase in HPV cell lines (SCC72 
and SCC89) after stimulation with 1 µg/mL of LPS. SCC2 and SCC90 (HPV+) did not show increase of IL-6 expression after stimulation 
(*p < 0.05, **p < 0.01; ***p < 0.001; Mean ± SEM); (C) Increase of protein levels of IL-6 in SCC89 after stimulation with 0.1 µg/mL and 1 µg/
mL of LPS (**p < 0.01; ***p < 0.001; Mean ± SD); (D) SCC72 showed significant increase of IL-6 after stimulation with 1 µg/mL of LPS-UP 
(*p < 0.01; Mean ± SD); (E) Only HPV+ cell lines showed no IL-8 gene expression, relative to the untreated, after stimulation with LPS (*p 
< 0.05; Mean ± SD); (F) Increase of IL-8 in SCC72 after stimulation with 1 µg/mL of LPS-UP, relative to the untreated (*p = 0.0353; Mean 
± SD); (G and H) Increase of IL-8 in SCC72 after stimulation with 0.01, 0.1 and 1 µg/mL of LPS (***p < 0.0001; Mean ± SD).
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angiogenesis [37, 38] and reinforcing tumor drug 
resistance [39]. Similarly, IL-8 promotes a number of 
responses implicated with tumor progression, including 
angiogenesis, increased tumor proliferation & survival, and 
neutrophil chemo-attraction [35]. Moreover, IL-8 has been 
correlated to metastasis, as seen in orthotopic, xenograft 
and nude mouse models [40, 41]. In this context, increased 
levels of IL-8 confer resistance to chemotherapeutic agents 
in tumor cells [33] and its inhibition correlates to better 
tumor response to therapy [35]. Given the extensive 
tumor-promoting functions reported for both IL-6 and 
IL-8, dysfunction of the TLR4 signaling pathway which 
thereafter leads to reduced secretion of IL-6 and IL-8, 
could contribute to a better tumor prognosis, as seen in 
patients with HPV+ OPSCC. 
Polymorphisms of TLRs have been associated 
with many diseases, and may be a risk factor linked to 
cervical cancer [42]. In addition to TLR4 polymorphisms, 
dysregulation of adapter molecules offers a further 
mechanism through which TLR4 function may be 
disrupted. For example, HeLa cells express TLR4 but 
not MD2, which is required for the activation of TLR4 
in response to PAMPs [43]. Molecules such as CD14 and 
MD2 are also essential for LPS recognition and activation 
of the signaling pathway [44]. 
TLR9 has been the focus of numerous studies 
into cervical carcinoma, due to this receptor acting as 
a method of HPV recognition [45]. A decrease in host 
epithelial TLR9 expression may offer an opportunity 
for HPV to more effectively evade the immune system, 
thereby allowing viral persistence within infected cells. 
This deficiency may be further compounded by the TLR9-
inhibiting effects of the E7 oncogene, once viral infection 
in established. The HPV16 virion has also been found to 
inhibit the transcriptional activity of TLR9 [45]. Despite 
the potential for downregulated TLR9 to be associated 
with viral infection, our findings were to the contrary, 
with higher expression observed in HPV+ lines and lower 
expression in HPV lines. 
Interestingly, Parroche et al., 2016, demonstrated 
downregulation of TLR9 in HNC (HPV negative) and 
showed that TLR9 induced a slowdown in the S-phase 
in HNC mediated by p16ink4a [46], a protein highly 
expressed in HPV+ tumors. In our work, TLR9 was more 
highly expressed in HPV+ OPSCC when compared with 
HPV and p16 expression was also higher in HPV+ cell 
lines and tumor specimens (data not shown). Moreover, 
HPV+ OPSCC show better prognosis which could be 
influenced by the slowdown of the cell cycle caused by 
p16ink4a, as demonstrated by these authors. 
In cervical cancer, studies have also shown increased 
expression of TLR9 in those patients who eliminated the 
virus [15], however this increase in TLR9 may be linked 
to viral clearance rather than being a characteristic feature 
of HPV+ cervical disease [47]. 
There are many possible explanations for the poor 
correlation we have observed between mRNA and protein 
expression in TLRs 1, 2, 4, 6 and 9 including variations 
in mRNA half-life [48, 49], and rates of recycling and 
degradation of proteins. Discrepancies between mRNA and 
protein expression such as this are not unusual, with only 
approximately 40% of reported mRNA levels correlating 
with protein expression [50, 51]. Our study has assessed 
TLR4 status using flow cytometry, a technique which 
allows detection of cell surface protein and not endocytosed 
receptor. TLR4 could be internalized and not detected 
during the usual cellular processes of storage and recycling 
[52], and thus membranous TLR4 would not correlate with 
Figure 6: Expression of TLR9 in HPV (SCC72 and SCC89), HPV16+ (SCC2 and SCC90) and HPV18+ (Hela). 
(A) TLR9 gene expression, relative to SCC72, by qPCR, shows only significant difference between SCC72 and SCC2 (*p < 0.05); 
(B) Median Fluorescence intensity (MFI), analyzed by flow cytometry, show significant higher expression in HPV+ cell lines (SCC2 and 
SCC90) compared to HPV cell lines (SCC72 and SCC89) (*p < 0.01; Mean ± SD).
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either mRNA expression or immunohistochemical staining 
of cytoplasm within tumor specimens. This is demonstrated 
by the immunohistochemistry stain where is possible to see 
a very strong stain in the cytoplasm, which may represent 
internalized TLR4. 
TLRs 3, 5, 7 and 8 appear to exert anti-tumor effects 
by converting immune tolerance into anti-tumor immunity 
[8]. Our results suggest that TLR3 expression does not 
correlate with HPV status of cell lines, findings which are 
consistent with previous studies on TLR3 expression in 
HPV+ OPSCC, in vivo [13]. TLR5 also appears to have 
potent antitumor effects in animal models. The only study 
of TLR5 in OPSCC demonstrated a decrease in TLR5 in 
OPSCC p16+ [13]. TLR7 in dendritic cells appears to have 
immunomodulatory and anti-tumor potential [53], but 
little is known about the contribution of this receptor in 
carcinogenesis [8]. TLR8 and TLR10 were not expressed 
in any of the OPSCC lineages studied and further 
investigations are required. 
In summary, we report that of the TLRs, only TLR1 
and TLR6 demonstrated reduced mRNA expression in 
HPV+ lineages compared to HPV-, and that TLR1, 2, 4, 6 
and 9 proteins were expressed in all cell lines, irrespective 
of HPV-status. TLR9 was upregulated in HPV+ OPSCC 
cell lines, which may represent a cellular response to viral 
infection. After stimulation with PGN, both HPV and 
one HPV+ cell lines expressed IL-6 and/or IL-8. We have 
furthermore demonstrated lower expression of TLR4 in 
HPV+ OPSCC compared to HPV OPSCC tumor tissue, 
as well as a lack of IL-6 and IL-8 expression in HPV+ 
cell lines after stimulation with both LPS and LPS-UP, 
inferring functional changes in the TLR4 signaling 
pathway of HPV+ disease. This work demonstrates a 
comprehensive survey of TLR expression and function in 
both HPV+ and HPV OPSCC.
MATERIALS AND METHODS
Ethical approval was obtained from the School of 
Dentistry/University of São Paulo Ethical Committee.
Cell lines and cell cultures
Experiments were carried out using two HPV16-
associated oropharyngeal carcinoma cell lines (SCC2 
and SCC90) and two HPV negative oropharyngeal 
carcinoma cell lines (SCC72 and SCC89) (Supplementary 
Table 1). The cells were received under material transfer 
agreement from Prof. Susanne M. Gollin, University 
of Pittsburgh and tested to confirmed HPV status by 
PCR using HPV 16E1 (Applied Biosystem, UK) in 
addition to a custom HPV16 E6 probe using previously 
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tandem repeat (STR) profiling was undertaken to 
confirm cell line authenticity. HeLa and THP1 cell lines 
were used as controls [55] (Supplementary Table 1). 
Monolayer cultures were grown in Dulbeccos Modified 
Eagles Medium (DMEM) (Sigma-Aldrich, Dorset, UK) 
supplemented with 10% FBS and 1 mmol/L L-glutamine 
and penicillin-streptomycin. THP1 cells were cultured in 
suspension using RPMI 1640 medium (Sigma-Aldrich, 
Dorset, UK). Cells were grown in a humidified incubator 
(5% CO2) at 37°C. 
RNA extraction and analysis
RNA was isolated using RNeasy Mini Kit (Qiagen, 
Manchester, UK) and treated with DNase I (Qiagen, 
Valencia, CA, USA). The quantity and quality of RNA 
were analyzed by NanoDrop Spectrophotometry (Thermo 
Scientific, Hemel Hempstead, UK). Reverse transcription 
was performed in 300 ng/ml of total RNA using High 
Capacity cDNA Reverse Transcription (Applied Biosystems, 
California, USA) in a final volume of 10 mL. Samples 
were incubated at 25°C for 10 min, 37°C for 2 h, 85°C for 
5 min and then kept at 4°C using the DNA Engine Dyad 
thermal cycler. 
Supplementary Table 2 summarizes primer 
sequences used in the experiments. TLR4 and TLR9 
primers were based on previously published sequences 
[22]. IL-6, IL-8 and U6 primers were a gift from Dr. Daniel 
Lambert (University of Sheffield). Sequence specificity 
was confirmed using the NCBI-GenBank database and 
Primer-BLAST. Real-time PCR was performed on cDNA 
using SYBR green mastermix (Applied Biosystems). 
Experiments were run in triplicate for 40 cycles at 50°C 
for 2 min, 95°C for 10 min, 95°C for 15s, 60°C for 
1 min, using dissociation curve analysis to confirm no 
bimodal curve or abnormal amplification (Supplementary 
Figure 1). Fold differences in TLR1-10, IL-6 and IL-8 
gene expression were normalized to the housekeeping 
gene U6. The mean threshold cycle (Ct) reading, from 
each triplicate experiment, was used to calculate relative 
gene expression levels. qPCR was performed using an 
ABI 7900HT PCR machine (Life Technologies, Paisley, 
UK) and relative mRNA expression calculated using RQ 
Manager 1.2.1 (Life Technologies, Paisley, UK). Data 
analysis was then performed using 2ǻǻ&W
For comparative analyses, differences were assessed 
in terms of TLR expression between cell lines using SCC72 
as the calibration sample (random allocation). In the case of 
TLR2, TLR4, IL-6 and IL-8 expression, differences were 
assessed between control and stimulated cells (PGN or LPS 
or LPS-UP) from the same cell line. Ct values exceeding 
35 cycles were not considered amplified. Negative control 
consisted of the master mix, primers and sterile water.
Flow cytometry
Adherent cells were washed with FACs buffer 
(PBS, 0.1% sodium azide and 1% BSA) and detached 
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non-enzymatically, centrifuged and re-suspended at 
1 × 105 cells/ml in cold FACs buffer on ice. Cells were divided 
into 4 aliquots and incubated with either PE-conjugated 
anti-human CD281 (TLR, eBioscience, 12-001141), 
PE-eFluor 610-conjugated anti human CD282 (TLR2, 
eBioscience, 61-9922-41), Alexa Fluor700-conjugated 
anti human CD284 (TLR4 eBioscience, 569917-41) or 
anti-human CD286 biotinylated (TLR6, eBioscience, 14-
9069-80) for 20 min on ice, in the dark, followed by FACS 
buffer washes. Samples previously incubated with anti-
TLR6 biotinylated antibody were incubated for another 
20 min with Straptavidin FITC (eBioscience, 11-4317-
87). Cells were then washed, centrifuged and fixed with 
1% paraformaldehyde. For intracellular staining, cells 
were fixed in 1% paraformaldehyde, washed with FACS 
buffer, centrifuged and incubated with 0.1% saponin for 
15 min at room temperature and then washed, centrifuged, 
re-suspended in cold FACS buffer. Cell suspensions were 
then divided into 2 aliquots and incubated in the dark and 
on ice with either APC-conjugated anti human CD289 
(TLR9, eBioscience, 17-9099-80) or APC-conjugated 
IgG2a K Isotype control (eBioscience, 17-4321-41). 
Unstained cells were used as a further control. Experiments 
were undertaken in triplicate and data is presented as 
median fluorescence intensity (MFI). Flow cytometry was 
performed using the LSRII Flow Cytometer System and 
data analyzed using Flowing Software 2.5.
Western blotting
Cells were lysed using RIPA buffer (Sigma Aldrich, 
Poole, UK) containing protease and phosphatase inhibitors 
(Roche, West Sussex, UK). Samples were centrifuged 
and the supernatant assayed for total protein using BCA 
Protein Quantitation as per manufacturers protocol 
7KHUPR 6FLHQWLILF +HPHO +HPSVWHDG 8.  ȝJ RI
total protein was loaded onto 412% polyacrylamide 
precast gels (NuPAge Bis-tris mini gels, Novex). After 
transfer to nitrocellulose membranes using an iBlot Dry 
Blotting System (Life Technologies, CA, USA) for 7 min, 
the membranes were washed with Tris buffer and blocked 
with 5% dried milk in tris buffered saline containing 
0,05% tween-20, for 1 h and incubated overnight at 4°C 
with primary monoclonal antibody anti-TLR2 (1:2000, 
Abcam, ab108998) , or incubated for 1h with primary anti-
b-actin (1:3000, Sigma Aldrich, Poole, UK). Membranes 
were then incubated in horseradish peroxidase-conjugated 
anti-rabbit IgG (1:3000) for 1 h and developed with 
SuperSignal West Pico chemiluminescent substrate 
(Thermo Scientific, Hemel Hempstead, UK). THP1 lysate 
was used as a positive control.
Stimulation of OPSCC cell lines with LPS,  
LPS-UP and PGN 
SCC24, SCC90, SCC72, SCC89 were stimulated 
with various concentrations of lipopolysaccharide (LPS: a 
non-specific TLR4 agonist) from Escherichia coli 0111:B4 
(Sigma-Aldrich, St. Louis, MO, USA), lipopolysaccharide 
ultra-pure (LPS-UP: a specific TLR4 agonist) from 
E. coli (In vivo Gen, San Diego, California, USA), and 
peptidoglycan from Staphylococcus aureus (PGN: a 
TLR2 agonist) (Sigma-Aldrich, St. Louis, MO, USA). 
For ELISA, cells were stimulated with 0.011 µg/mL 
of LPS; 0.01-1 µg/mL of LPS-UP and 0.110 µg/mL of 
PGN [25, 56]. For qPCR and Western blot, cells were 
stimulated with 1 µg/mL of LPS or LPS-UP or PGN. All 
incubations were undertaken in a humidified incubator 
(5% CO2) at 37°C for 24 h. Experiments were undertaken 
using triplicate biological repeats. 
Measurement of cytokine levels
LPS, LPS-UP and PGN were added to keratinocyte 
monolayers (SCC2, SCC90, SCC72 and SCC90) in 
T25 flasks. Culture supernatants were collected in order 
to measure cytokine levels of IL-6 and IL-8, using BD 
OptEIA Human IL-6 and BD OptEIA Human IL-8 ELISA 
kits (BD Biosciences, Torreyana Road, San Diego, CA, 
USA).
Analysis of TLR4 expression in OPSCC tissue
We analyzed TLR4 expression in 61 FFPE 
oropharyngeal tumor samples in a tissue microarray 
(TMA) consisting of 31 HPV+ oropharyngeal carcinomas 
(Supplementary Table 3) and 30 HPV carcinomas 
(Supplementary Table 4) (from Prof. Mark Lingen, 
University of Chicago). Two 1 mm cores, taken from the 
body of each tumor were available for each case. The TMA 
slide was incubated overnight at 37°C, then deparaffinized 
and hydrated and washed with Tris buffer. This was 
followed by antigen retrieval in 10 mM sodium citrate (pH 
6.0) at 95°C for 30 mins, and quenching in 3% hydrogen 
peroxide for 15 min. Blocking of nonspecific binding 
was undertaken using 5% BSA at room temperature for 
30 mins. The tissue was then incubated overnight at 4°C 
with Monoclonal Anti-TLR4 (1:1000, Abcam, ab22048), 
followed by the Envision Dual Link System horseradish 
peroxidase method. Staining was then revealed by the 
addition of di-aminobenzidine (DAB) substrate-chromogen 
and the TMA was counterstained, dehydrated and mounted. 
Semi-automated quantification of histochemical 
staining by color deconvolution
Digital image of IHC-stained TMA slide was 
obtained using a digital slide scanner (ScanScope-Aperio). 
Tumor area was then calculated using ImageJ software, by 
selecting the region of interest using the measure tool. 
Each spot image was submitted to color deconvolution 
[57] to separate the blue color from hematoxylin and 
the brown color from DAB using the plugin in ImageJ 
software (National Institute of Health). The positive 
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labeling (brown color) was selected using the threshold 
tool of ImageJ (from 0 to 127 brown tones). The final 
score was calculated as [(positive labeling area/tumor 
area) ×100)].
Statistical analysis 
Statistical analysis was undertaken using GraphPad 
Prism software version 6.0 (GraphPad Prism Software, 
San Diego, CA, USA). For qPCR data, results are 
expressed as mean ± SEM, and statistical significance 
assessed using one-way ANOVA post hoc Tukey analysis 
to compare more than 2 groups and t-Student to compare 
two independent groups. For flow cytometry data, after 
failure of normality testing, the non-parametric Kruskal-
Wallis test with post hoc Dunn-Bonferroni correction was 
used. Graphs depict mean MFI ± SD. Analysis of ELISA 
data was undertaken through comparison of stimulated 
samples (LPS, LPS-UP or PGN) against unstimulated 
control, using the Mann-Whitney U-test. Graphs are 
expressed as pg/mL and mean ± SD. The Mann-Whitney 
U test was also used to compare TLR4 staining between 
HPV+ and HPV tumors. All statistical tests were 
undertaken with the significance level set at p < 0.05. 
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